Filing Flows › Evofem Biosciences (EVFM) › Q2 2026 › vs Q1 2026
Evofem Biosciences (EVFM) Q2 2026 vs Q1 2026 (quarter over quarter)
Evofem Biosciences's revenue rose $1.7M (+193%) from $899K in Q1 2026 to $2.6M in Q2 2026.
Evofem Biosciences, Q2 2026: revenue $2.6M (-45% year over year), operating margin -94.5%, net loss $11.0M, operating cash flow −$3.1M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $2.6M | $899K | $1.7M | +193% |
| Net loss | $11.0M | $5.5M | $5.6M | +102% |
| Costs & expenses | $13.7M | $6.4M | $7.3M | +115% |
| Operating costs | $5.1M | $5.5M | −$346K | -6% |
| Interest & other, net | $8.5M | $897K | $7.7M | +853% |
| Cost of revenue | $511K | $410K | $101K | +25% |
| Sales & marketing | $2.1M | $2.1M | −$18K | -0.9% |
| General & admin | $1.8M | $2.4M | −$544K | -23% |
| Other operating costs | $708K | $593K | $115K | +19% |
| Operating cash sources | $11.0M | $5.5M | $5.6M | +102% |
| Depreciation & amortization | $18K | $79K | −$61K | -77% |
| Working capital & other | $7.9M | $7.7M | $206K | +3% |
| Cash used in operations | $3.1M | −$2.3M | $5.4M | — |
| Net loss absorbed | $11.0M | $5.5M | $5.6M | +102% |
Questions
How much did Evofem Biosciences's revenue grow quarter over quarter in Q2 2026?
Evofem Biosciences's revenue rose $1.7M (+193%) from $899K in Q1 2026 to $2.6M in Q2 2026.